Ferrán Ferrer

Institut Català d'Oncologia

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Ferràn Guedea

Institut Català d'Oncologia

J. Pera

Institut Català d'Oncologia

Xavier García del Muro

Institut Català d'Oncologia

S. Villá

Hospital Universitari Germans Trias i Pujol

Cristina Gutiérrez

Institut Català d'Ornitologia

Francesc Vigués

Bellvitge University Hospital

Begoña P. Valderrama

Hospital Universitario Virgen del Rocío

Ana Medina

Centro Oncológico de Galicia

G. Lendínez-Cano

Universidad de Sevilla

Regina Gironés Sarrió

Hospital Universitari i Politècnic La Fe

Cooperative Institutions

Institut Català d'Oncologia

Universitat de Barcelona

Bellvitge University Hospital

Hospital Del Mar

Municipal Institute for Medical Research

Hospital del Mar Research Institute

Universitat Autònoma de Barcelona

Hospital Clínic de Barcelona

Institut d'Investigació Biomédica de Bellvitge

Institut Català d'Ornitologia

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial

Xavier García del Muro Begoña P. Valderrama Ana Medina Olatz Etxániz Regina Gironés Sarrió

Supplementary Figure 4. Phenotype profiling of immune populations by flow cytometry in patients treated with standard of care (SOC), radiotherapy and chemotherapy plus cystectomy. A) Percentage of immune cellsRadar plots, showing the mean amount of cells/mL in blood, for each immune population grouped by treatment cohort at baseline (Basal), one week of treatment (1W), end of treatment (EOT) and 1-3 months after the EOT (ATm). B) Percentage of cells within CD8 or CD4 T populations (mean+SE). Statistics comparisons between each timepoint with the basal levels (U Mann-Whitney test, * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001).

Durvalumab

Tremelimumab

Chemo-radiotherapy

10.1158/1078-0432.28428232

Cite

Citations (0)

Data from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial

Xavier García del Muro Begoña P. Valderrama Ana Medina Olatz Etxániz Regina Gironés Sarrió

<div>AbstractPurpose:The combination of radiation and immunotherapy potentiated antitumor activity in preclinical models. The purpose of this study is to explore the feasibility, safety, and efficacy of a bladder-preserving approach, including dual immune checkpoint blockade and radiotherapy, in patients with muscle-invasive bladder cancer (MIBC).Patients and Methods:Patients with localized MIBC underwent transurethral resection, followed by durvalumab (1,500 mg) plus tremelimumab (75 mg) every 4 weeks for three doses and concurrent radiotherapy (64–66 Gy to bladder). Patients with residual or relapsed MIBC underwent salvage cystectomy. The primary endpoint was complete response, defined as the absence of MIBC at posttreatment biopsy. Secondary endpoints were bladder-intact disease-free survival, distant metastasis–free survival, and overall survival.Results:Thirty-two patients were enrolled at six centers. Complete response was documented in 26 (81%) patients. Two patients had residual MIBC, and four patients were not evaluated. After a median follow-up of 27 months, 2 patients underwent salvage cystectomy. The 2-year rates for bladder-intact disease-free survival, distant metastasis–free survival, and overall survival were 65%, 83%, and 84%, respectively. The 2-year estimates of non–muscle-invasive bladder relapse, MIBC, and distant metastasis were 3%, 19%, and 16%, respectively. Grade 3 to 4 toxicities were reported in 31% of patients, with diarrhea (6%) and acute kidney failure (6%) being the most frequent.Conclusions:This multimodal approach including durvalumab plus tremelimumab with concurrent radiotherapy is feasible and safe, showing high efficacy in terms of response and eliciting bladder preservation in a large number of patients. Further research on this approach as an alternative to cystectomy is warranted.</div>

Durvalumab

Tremelimumab

10.1158/1078-0432.c.7676176

Cite

Citations (0)

Acute Toxicity Report for Combined Sorafenib and Radiation Treatment in Phase 1 Multicentric Trial for Conservative Management of Bladder Cancer

International Journal of Radiation Oncology*Biology*Physics (2013)

Ferrán Ferrer Gemma Sancho Á. Rovirosa Pablo Maroto Begoña Mellado

10.1016/j.ijrobp.2013.06.217

Cite

Citations (0)

External Beam Radiation Therapy Plus High-Dose-Rate Brachytherapy in the Treatment of Locally Advanced Prostate

Brachytherapy (2016)

Ferràn Guedea Cristina Gutiérrez A. Boladeras L. Santorsa Ferrán Ferrer

External beam radiation

Dose rate

External beam radiotherapy

10.1016/j.brachy.2016.04.339

Cite

Citations (0)

Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis

The Prostate (2016)

Laura Foj Ferrán Ferrer Mireia Llauradó‐Serra Antonio Guardiola Arévalo Montserrat Gavagnach

BACKGROUND MicroRNAs (miRNAs) are non-coding small RNAs, involved in post-transcriptional regulation of many target genes. METHODS Five miRNAs that have been consistently found deregulated in PCa (miR-21, miR-141, miR-214, miR-375, and let-7c) were analyzed in urinary pellets from 60 prostate cancer (PCa) patients and 10 healthy subjects by qRT-PCR. Besides, urinary exosomes were isolated by differential centrifugation and analyzed for those miRNAs. RESULTS Significant upregulation of miR-21, miR-141, and miR-375 was found comparing PCa patients with healthy subjects in urinary pellets, while miR-214 was found significantly downregulated. Regarding urinary exosomes, miR-21 and miR-375 were also significantly upregulated in PCa but no differences were found for miR-141. Significant differences were found for let-7c in PCa in urinary exosomes while no differences were observed in urinary pellets. A panel combining miR-21 and miR-375 is suggested as the best combination to distinguish PCa patients and healthy subjects, with an AUC of 0.872. Furthermore, the association of miRNAs with clinicopathological characteristics was investigated. MiR-141 resulted significantly correlated with Gleason score in urinary pellets and let-7c with clinical stage in urinary exosomes. Additionally, miR-21, miR-141, and miR-214 were found significantly deregulated in intermediate/high-risk PCa versus low-risk/healthy subjects in urinary pellets. Significant differences between both groups were found in urinary exosomes for miR-21, miR-375, and let-7c. CONCLUSIONS These findings suggest that the analysis of miRNAs—especially miRNA-21 and miR-375- in urine could be useful as biomarkers in PCa. Prostate 77: 573–583, 2017. © 2016 Wiley Periodicals, Inc.

10.1002/pros.23295

Cite

Citations (158)

Hematological Toxicity in Lung Cancer

Medical radiology (2011)

Francesc Casas Ferrán Ferrer Núria Viñolas

10.1007/174_2011_271

Cite

Citations (1)

Quality of Life Impact of Treatments for Localized Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics (2013)

Ferrán Ferrer Ferràn Guedea Yolanda Pardo Montse Ferrer J. Suárez